- Home
- IMMX vs CLST Comparison
IMMX vs CLST Comparison
Compare IMMX & CLST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- CLST
- Stock Information
- Founded
- IMMX 2014
- CLST 1922
- Country
- IMMX United States
- CLST United States
- Employees
- IMMX N/A
- CLST N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- CLST
- Sector
- IMMX Health Care
- CLST
- Exchange
- IMMX Nasdaq
- CLST Nasdaq
- Market Cap
- IMMX 65.5M
- CLST 54.6M
- IPO Year
- IMMX 2021
- CLST N/A
- Fundamental
- Price
- IMMX $2.47
- CLST $13.32
- Analyst Decision
- IMMX Strong Buy
- CLST
- Analyst Count
- IMMX 1
- CLST 0
- Target Price
- IMMX $8.00
- CLST N/A
- AVG Volume (30 Days)
- IMMX 221.4K
- CLST 3.9K
- Earning Date
- IMMX 11-11-2025
- CLST 10-23-2025
- Dividend Yield
- IMMX N/A
- CLST N/A
- EPS Growth
- IMMX N/A
- CLST N/A
- EPS
- IMMX N/A
- CLST 0.58
- Revenue
- IMMX N/A
- CLST $11,354,000.00
- Revenue This Year
- IMMX N/A
- CLST N/A
- Revenue Next Year
- IMMX N/A
- CLST N/A
- P/E Ratio
- IMMX N/A
- CLST $23.06
- Revenue Growth
- IMMX N/A
- CLST 164.54
- 52 Week Low
- IMMX $1.34
- CLST $10.67
- 52 Week High
- IMMX $3.20
- CLST $14.23
- Technical
- Relative Strength Index (RSI)
- IMMX 67.32
- CLST 70.69
- Support Level
- IMMX $1.94
- CLST $13.00
- Resistance Level
- IMMX $2.13
- CLST $13.22
- Average True Range (ATR)
- IMMX 0.16
- CLST 0.06
- MACD
- IMMX 0.05
- CLST 0.01
- Stochastic Oscillator
- IMMX 99.45
- CLST 92.14
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About CLST Catalyst Bancorp Inc.
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.